Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: Preliminary patient results

Joanne M. Wells, David A. Mankoff, Janet F. Eary, Alexander M. Spence, Mark Muzi, Finbarr O'Sullivan, Cheryl B. Vernon, Jeanne Link, Kenneth Krohn

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

2-[11C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport (K1t) and thymidine flux (K TdR) into brain tumors and normal brain. These estimates were compared to MRI and pathologic results. Methods: Twenty patients underwent sequential [11C]CO2 (major TdR metabolite) and TdR PET studies with arterial blood sampling and metabolite analysis. The data were fitted using the five-compartment model described in the companion article. Results: Comparison of model estimates with clinical and pathologic data shows that K1t is higher for MRI contrast enhancing tumors (p <.001), and KTdR increases with tumor grade (p <.02). On average, TdR retention was lower after treatment in high-grade tumors. The model was able to distinguish between increased thymidine transport due to blood-brain barrier breakdown and increased tracer retention associated with tumor cell proliferation. Conclusion: Initial analysis of model estimates of thymidine retention and transport show good agreement with the clinical and pathological features of a wide range of brain tumors. Ongoing studies will evaluate its role in measuring response to treatment and predicting outcome.

Original languageEnglish (US)
Pages (from-to)145-150
Number of pages6
JournalMolecular Imaging
Volume1
Issue number3
DOIs
StatePublished - Jul 2002
Externally publishedYes

Fingerprint

Brain Neoplasms
Thymidine
Tumors
Brain
Imaging techniques
Kinetics
Neoplasms
Metabolites
Cell Proliferation
Magnetic resonance imaging
Blood-Brain Barrier
Cell proliferation
Blood
Therapeutics
Fluxes
Sampling
Monitoring

Keywords

  • [C]Thymidine
  • Brain tumors
  • Kinetic modeling
  • PET
  • Proliferation

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors : Preliminary patient results. / Wells, Joanne M.; Mankoff, David A.; Eary, Janet F.; Spence, Alexander M.; Muzi, Mark; O'Sullivan, Finbarr; Vernon, Cheryl B.; Link, Jeanne; Krohn, Kenneth.

In: Molecular Imaging, Vol. 1, No. 3, 07.2002, p. 145-150.

Research output: Contribution to journalArticle

Wells, Joanne M. ; Mankoff, David A. ; Eary, Janet F. ; Spence, Alexander M. ; Muzi, Mark ; O'Sullivan, Finbarr ; Vernon, Cheryl B. ; Link, Jeanne ; Krohn, Kenneth. / Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors : Preliminary patient results. In: Molecular Imaging. 2002 ; Vol. 1, No. 3. pp. 145-150.
@article{ef237c66285c4e76b739621121b72e59,
title = "Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: Preliminary patient results",
abstract = "2-[11C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport (K1t) and thymidine flux (K TdR) into brain tumors and normal brain. These estimates were compared to MRI and pathologic results. Methods: Twenty patients underwent sequential [11C]CO2 (major TdR metabolite) and TdR PET studies with arterial blood sampling and metabolite analysis. The data were fitted using the five-compartment model described in the companion article. Results: Comparison of model estimates with clinical and pathologic data shows that K1t is higher for MRI contrast enhancing tumors (p <.001), and KTdR increases with tumor grade (p <.02). On average, TdR retention was lower after treatment in high-grade tumors. The model was able to distinguish between increased thymidine transport due to blood-brain barrier breakdown and increased tracer retention associated with tumor cell proliferation. Conclusion: Initial analysis of model estimates of thymidine retention and transport show good agreement with the clinical and pathological features of a wide range of brain tumors. Ongoing studies will evaluate its role in measuring response to treatment and predicting outcome.",
keywords = "[C]Thymidine, Brain tumors, Kinetic modeling, PET, Proliferation",
author = "Wells, {Joanne M.} and Mankoff, {David A.} and Eary, {Janet F.} and Spence, {Alexander M.} and Mark Muzi and Finbarr O'Sullivan and Vernon, {Cheryl B.} and Jeanne Link and Kenneth Krohn",
year = "2002",
month = "7",
doi = "10.1162/153535002760235445",
language = "English (US)",
volume = "1",
pages = "145--150",
journal = "Molecular imaging : official journal of the Society for Molecular Imaging",
issn = "1535-3508",
publisher = "Decker Publishing",
number = "3",

}

TY - JOUR

T1 - Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors

T2 - Preliminary patient results

AU - Wells, Joanne M.

AU - Mankoff, David A.

AU - Eary, Janet F.

AU - Spence, Alexander M.

AU - Muzi, Mark

AU - O'Sullivan, Finbarr

AU - Vernon, Cheryl B.

AU - Link, Jeanne

AU - Krohn, Kenneth

PY - 2002/7

Y1 - 2002/7

N2 - 2-[11C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport (K1t) and thymidine flux (K TdR) into brain tumors and normal brain. These estimates were compared to MRI and pathologic results. Methods: Twenty patients underwent sequential [11C]CO2 (major TdR metabolite) and TdR PET studies with arterial blood sampling and metabolite analysis. The data were fitted using the five-compartment model described in the companion article. Results: Comparison of model estimates with clinical and pathologic data shows that K1t is higher for MRI contrast enhancing tumors (p <.001), and KTdR increases with tumor grade (p <.02). On average, TdR retention was lower after treatment in high-grade tumors. The model was able to distinguish between increased thymidine transport due to blood-brain barrier breakdown and increased tracer retention associated with tumor cell proliferation. Conclusion: Initial analysis of model estimates of thymidine retention and transport show good agreement with the clinical and pathological features of a wide range of brain tumors. Ongoing studies will evaluate its role in measuring response to treatment and predicting outcome.

AB - 2-[11C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport (K1t) and thymidine flux (K TdR) into brain tumors and normal brain. These estimates were compared to MRI and pathologic results. Methods: Twenty patients underwent sequential [11C]CO2 (major TdR metabolite) and TdR PET studies with arterial blood sampling and metabolite analysis. The data were fitted using the five-compartment model described in the companion article. Results: Comparison of model estimates with clinical and pathologic data shows that K1t is higher for MRI contrast enhancing tumors (p <.001), and KTdR increases with tumor grade (p <.02). On average, TdR retention was lower after treatment in high-grade tumors. The model was able to distinguish between increased thymidine transport due to blood-brain barrier breakdown and increased tracer retention associated with tumor cell proliferation. Conclusion: Initial analysis of model estimates of thymidine retention and transport show good agreement with the clinical and pathological features of a wide range of brain tumors. Ongoing studies will evaluate its role in measuring response to treatment and predicting outcome.

KW - [C]Thymidine

KW - Brain tumors

KW - Kinetic modeling

KW - PET

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=0013148568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0013148568&partnerID=8YFLogxK

U2 - 10.1162/153535002760235445

DO - 10.1162/153535002760235445

M3 - Article

C2 - 12920852

AN - SCOPUS:0013148568

VL - 1

SP - 145

EP - 150

JO - Molecular imaging : official journal of the Society for Molecular Imaging

JF - Molecular imaging : official journal of the Society for Molecular Imaging

SN - 1535-3508

IS - 3

ER -